TransMedics Group $150 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised representatives of the underwriters in connection with the $150 million SEC-registered follow-on offering of 3,737,500 shares of common stock of TransMedics Group, Inc., which included 487,500 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. The common stock is listed on the Nasdaq Global Market under the symbol “TMDX.”
TransMedics Group, Inc. is a commercial-stage medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure.
The Davis Polk capital markets team included partner Richard D. Truesdell, Jr. and associates Jakub P. Jozwiak and Katherine Warshauer. Partner David R. Bauer and associates Alison T. Chin and Alexis N. Wallace provided intellectual property advice. The tax team included partner Mario J. Verdolini and associates Justin Corvino and April Filtz. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.